Biora Therapeutics Announces New Patent Covering Its BioJet Liquid Jet Delivery Technology
Biora Therapeutics Announces New Patent Covering Its BioJet Liquid Jet Delivery Technology
Biora Therapeutics, Inc. (NASDAQ:BIOR), the biotech company that is reimagining therapeutic delivery, today announced the issuance of a new patent related to the company's BioJet platform for oral, systemic delivery of biotherapeutics, which uses an ingestible device designed to achieve systemic uptake through liquid jet delivery to the small intestine.
正在重新构想治疗给药的生物技术公司Biora Therapeutics, Inc.（纳斯达克股票代码：BIOR）今天宣布发布一项与该公司用于口服、全身输送生物疗法的BioJet平台有关的新专利，该平台使用一种可吸收的设备，旨在通过液体喷射输送到小肠来实现全身吸收。
The United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,938,295 entitled, "Ingestible Device for Delivery of Therapeutic Agent to the Gastrointestinal Tract." The issued claims cover key jet parameters for liquid jet delivery of a drug to the gastrointestinal (GI) tract, including the stomach or small intestine.
美国专利商标局（USPTO）已颁发了第11,938,295号美国专利，题为 “向胃肠道输送治疗剂的可摄入装置”。发布的索赔涵盖了液体喷射向胃肠道（GI）（包括胃或小肠）输送药物的关键喷射参数。
"This latest patent further secures Biora's broad and comprehensive ownership of liquid jet delivery to the GI tract. The BioJet platform's liquid jet injection technology, with systemic bioavailability and consistency shown to be comparable to traditional subcutaneous injection, is outperforming our performance targets in preclinical testing," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "Our approach also allows for the delivery of multi-milligram doses of nearly any liquid drug, with minimal to no reformulation. The BioJet platform's potential to deliver large molecules, including GLP-1 agonists, monoclonal antibodies, antisense oligonucleotides, and many others, and to achieve liver-targeted delivery through the hepatic portal, could transform oral delivery of therapeutics," stated Mr. Mohanty.
“这项最新专利进一步确保了Biora对向胃肠道输送液体喷射的广泛而全面的所有权。Biora Therapeutics首席执行官阿迪·莫汉蒂说，BioJet平台的液体喷射注射技术已证明其全身生物利用度和一致性与传统皮下注射相当，其表现超过了我们在临床前测试中的性能目标。“我们的方法还允许输送几乎所有液体药物的数毫克剂量，几乎无需重新配方。BioJet平台有可能提供大分子，包括 GLP-1 激动剂、单克隆抗体、反义寡核苷酸等，并有可能通过肝门实现肝脏靶向输送，这可能会改变治疗药物的口服给药，” 莫汉蒂说。
Biora holds a comprehensive patent position for the BioJet systemic oral delivery platform, with approximately 12 issued patents and 31 pending applications that cover its delivery platform and methods for using the platform to treat a disease or condition in a patient using liquid jet delivery of a wide range of drugs. These patents are part of Biora's larger corporate portfolio consisting of 73 patent families, including approximately 190 issued patents and 136 pending applications in major jurisdictions around the world, including the US, Europe, Canada, China, Japan, South Korea, Israel, Australia and Mexico.
Biora拥有BioJet系统性口服给药平台的全面专利地位，约有12项已颁发的专利和31项待批申请，涵盖了其交付平台以及使用该平台使用液体喷射输送各种药物治疗患者疾病或病症的方法。这些专利是Biora由73个专利家族组成的更大企业组合的一部分，包括在美国、欧洲、加拿大、中国、日本、韩国、以色列、澳大利亚和墨西哥等全球主要司法管辖区的大约190项已颁发的专利和136项待处理的申请。